FDA Grants Fast Track Designation to HTX-001 for nHCM

The US Food and Drug Administration (FDA) has granted Fast Track designation to HTX-001 for the treatment of nonobstructive hypertrophic cardiomyopathy (nHCM).¹

HAYA Therapeutics announced the designation on July 28, 2026. The designation provides access to an expedited development pathway for therapies intended to treat serious conditions and address an unmet medical need.¹

“Patients with nonobstructive HCM are seeking treatments that go beyond management of symptoms. This designation reflects the urgency of delivering better therapeutic options,” Jordan Shin, MD, PhD, chief medical officer of HAYA Therapeutics, said in a statement. “With our Phase I clinical trial already underway, Fast Track designation allows us to work more closely with the FDA as we advance HTX-001, our investigational precision RNA-guided therapy designed to reprogram disease-driving cardiac fibroblasts - the sentinel effector cells that act to drive fibrosis and remodeling in the myocardium.”¹

Fast Track status does not constitute marketing approval or establish efficacy or safety. Instead, the designation may provide more frequent interactions with the FDA during clinical development and permit rolling submission of portions of a new drug application or biologics license application when relevant requirements are met.²

What FDA Fast Track Designation Means for HTX-001

Under FDA guidance, Fast Track designation is available for drugs intended to treat serious conditions when nonclinical or clinical data demonstrate potential to address an unmet medical need. The evidence needed can vary according to the product’s development stage and the availability of existing treatments. Early in development, a mechanistic or nonclinical rationale may contribute to the agency’s assessment; later requests generally can incorporate clinical evidence.²

Benefits may include more frequent meetings and written communications with the FDA concerning study design, biomarker strategy, development plans, and data needed for a future application. A product also may become eligible for rolling review, allowing the agency to review completed application sections before receipt of the full submission. Fast Track products can be considered separately for priority review or accelerated approval if applicable criteria are satisfied.²

The designation does not guarantee use of those additional programs, a shortened clinical development timeline, acceptance of a marketing application, or eventual approval. Standard requirements for demonstrating safety, efficacy, and manufacturing quality remain in place.²

What Is Known About HTX-001 and the Supporting Evidence

HTX-001 is a differentiated antisense oligonucleotide, designed to downregulate the heart stress-specific lncRNA WISPER, which is overexpressed in HCM. Investigators believe that, by targeting WISPER in cardiac myofibroblasts, HTX-001 may promote precision reprogramming of this cell state towards a healthy phenotype.¹

A Phase I trial investigating HTX-001 is currently underway: on May 20, 2026, HAYA Therapeutics announced that the first cohort of patients had been fully dosed. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy patients and those with nHCM across a series of multiple-ascending dose cohorts.³

References

1. HAYA Therapeutics receives FDA Fast Track designation for HTX-001. Business Wire. Published July 28, 2026. https://www.businesswire.com/news/home/20260728393451/en/HAYA-Therapeutics-Receives-FDA-Fast-Track-Designation-for-HTX-001

2. US Food and Drug Administration. Expedited Programs for Serious Conditions—Drugs and Biologics: Guidance for Industry. Published May 2014.

3. HAYA Therapeutics. HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001. May 20, 2026. Accessed July 28, 2026. https://www.hayatx.com/haya-therapeutics-announces-first-cohort-dosed-in-phase-1-clinical-trial-of-htx-001-an-investigational-precision-cellular-reprogramming-therapy-for-cardiac-fibrosis/